By The ASCO Post Staff Posted: 9/29/2022 2:50:00 PM Last Updated: 9/29/2022 2:10:34 PM A research team led by Matthias Preusser, MD, PhD, Professor of Medical Oncology and Head of the Clinical Division of Oncology at the Medical University of Vienna, had already demonstrated that patients with cancer may…
A recent study explored the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in patients with metastatic uveal melanoma.
Investigators have uncovered persistent inequities in breast cancer that may systematically leave many patients behind in spite of recent improvements in research, treatment, and survival,…
Success stories in research, advocacy, and education from low- and middle-income countries deserve international recognition to motivate the next generation of researchers and practitioners and…
Concurrent cisplatin, gemcitabine, and intensity-modulated radiation therapy (IMRT) produced a high rate of complete pathologic response in patients with locally advanced vulvar squamous cell carcinom…
William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, details the fundamental shift in how clinicians now treat patients with…
The phase III CONTACT-01 trial evaluated atezolizumab plus cabozantinib vs docetaxel in patients with metastatic NSCLC after they had received checkpoint inhibitor treatment and chemotherapy.
A recent study examined whether glucagon-like peptide (GLP)-1 receptor agonists are associated with an increased risk of thyroid cancer.
In a single-center phase II trial, cabozantinib monotherapy showed activity in adult patients with advanced adrenocortical carcinoma.
Investigators have uncovered new genetic variants that may predispose certain female patients to prevalent or persistent HPV infections and increase their risk of developing cervical…
In a single-center phase II trial, cabozantinib monotherapy showed activity in adult patients with advanced adrenocortical carcinoma.
